drugset / Trial / NCT04874506
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Non-randomizedSequentialOpen-labelTreatment
Summary
MBM-02 (Tempol) is an HIF-1 and HIF-2 inhibitor that is being tested as an addition to standard of care treatment that includes radiotherapy and TMZ. MBM-02's ability to increase progression free survival and decrease side effects of TMZ and radiotherapy treatment will be assessed.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-01
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tempol | Small molecule | 1000 mg | Oral |
| Subject | Tempol | Small molecule | 1200 mg | Oral |
| Subject | Tempol | Small molecule | 1400 mg | Oral |